Alkem Laboratories FY25 Annual Earnings Summary
4 quarters covered · ₹6,518 Cr revenue · ₹8,363 Cr PAT · 10.7% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Promise tracking available after 2+ quarters of coverage.
Risks flagged during the year
The acute therapy market, especially anti-infectives, continues to show sluggish growth, impacting Alkem's high-acute portfolio.
Q4 FY25 · highContinued price erosion in the US generics market and potential tariffs could impact US business growth and margins.
Q4 FY25 · highTax rate is expected to rise to 35-37% from FY27 as MAT credit is utilized, significantly impacting net profit.
Q1 FY25 · mediumQ2 and Q3 typically see higher anti-infective sales, which could lower margins by ~2% due to product mix shift.
Q1 FY25 · mediumNew initiatives (CDMO, medical devices) will incur losses and impact EBITDA by ~0.5 ppt in H2, with breakeven expected only by FY26.
Q1 FY25 · mediumUS generic business faces single-digit price erosion; new product ramp-up may be slower than expected, limiting revenue contribution.
Q2 FY25 · mediumUS business faces ongoing price erosion (6% in Q2) and the need to regain lost contracts after past supply issues.
Q2 FY25 · mediumPartner Exactech is undergoing bankruptcy, which could disrupt technology transfer and launch timelines for the MedTech business.
Q2 FY25 · mediumBrands like Clavam and Xone have lost market share, partly due to increased competition from smaller players post-COVID.
Q3 FY25 · mediumPrice erosion in US generics is ~5% (2.5% on NRV basis) and expected to persist, pressuring US revenue growth.
Q3 FY25 · mediumIndia acute market growth slowed to 5.7% in Q3; Alkem's trade generics business (20% of domestic) was flat due to competition and pricing pressure.
Q3 FY25 · mediumChile business declined ~30% due to exiting a low-priced tender and Chilean peso depreciation; recovery uncertain.
What changed through the year
Q1 FY25 · Full-year EBITDA margin around 18%
Management expects EBITDA margin for FY25 to be around 18%, similar to last year, despite gross margin improvement, due to investments in new growth initiatives.
Q1 FY25 · Gross margin improvement of ~150 bps to 62.5%
Full-year gross margin expected to improve to 62.5% from 61% in FY24, driven by favorable API pricing and product mix.
Q1 FY25 · Domestic business growth in line with IPM (8-10%)
India business expected to grow in line with the Indian pharmaceutical market, which is projected at 8-10%.
Q1 FY25 · US business single-digit growth with new launches
US business expected to see single-digit growth, with Dabigatran contributing meaningfully from Q3/Q4.
Q2 FY25 · Domestic revenue growth of 8-9% for FY25
Management maintains full-year domestic growth guidance of 8-9%, with Q4 expected to be particularly strong.
Q2 FY25 · EBITDA margin improvement of ~100bps to 18.5-19% for FY25
Full-year EBITDA margin expected to be 18.5-19%, driven by cost controls and product mix improvement.
Q2 FY25 · US business flattish to mid-single-digit erosion for FY25
US revenue expected to decline flattish to mid-single-digit for the full year, with H2 performance better than H1.
Q2 FY25 · Enzyme plant commissioning by Q4 FY25 or Q1 FY26
The US biologic CDMO plant is expected to begin production by Q4 FY25 or Q1 FY26, with break-even targeted in the first year.
Q3 FY25 · Full-year EBITDA margin guidance maintained at 19%
Despite 21.6% margin in 9M, Q4 is seasonally weak with higher R&D spend (5 filings), so full-year margin expected around 19%.
Q3 FY25 · Domestic business to grow in line with IPM (~7%) for FY25
Q4 implied growth of ~9.5-10% driven by strong secondary optics and low base.
Q3 FY25 · US business expected to be flat YoY in Q4
Improved from -22% in Q2 to -7% in Q3; supply normalization should lead to neutral growth by Q4.
Q3 FY25 · Semaglutide launch in first wave in India
Alkem has developed its own product, filed with regulator, and plans to be among the first to launch.
Q4 FY25 · EBITDA margin guidance of ~19.5% for FY26
Management expects EBITDA margins to remain stable at around 19.5% in FY26, supported by operating leverage and despite higher R&D investments.
Q4 FY25 · US business mid-single-digit growth in FY26
US revenue is expected to grow at a mid-single-digit rate in FY26, driven by 5-6 new product launches and improved supply.
Q4 FY25 · Domestic business to outperform IPM by 100 bps in FY26
India business is expected to grow at least 100 basis points above the IPM growth rate of 7-8%.
Q4 FY25 · CapEx of INR 700-750 crore in FY26
Capital expenditure for FY26 is guided at INR 700-750 crore, including ~INR 200 crore for the Engine CDMO plant and routine maintenance.